Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.49 |
| ▸ | JAK3 | P52333 | 8/20 | 0.49 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | SLC2A3 | P11169 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27249103 | 0.85 | ROCK2 (0.57) | NPC1RAB9ADGAT1SLC2A1SLC2A3 | |
| SCHEMBL27248949 | 0.81 | SLC2A1 (0.53) | NPC1RAB9ADGAT1SLC2A1SLC2A3 | |
| SCHEMBL31173601 | 0.81 | SLC2A1 (0.53) | NPC1RAB9ADGAT1SLC2A1SLC2A3 | |
| SCHEMBL27248767 | 0.80 | SLC2A1 (0.51) | NPC1RAB9ADGAT1SLC2A1SLC2A3 | |
| SCHEMBL27249066 | 0.80 | ROCK2 (0.52) | SLC2A1SLC2A3 | |
| SCHEMBL27248907 | 0.78 | HDAC3 (0.51) | DGAT1SLC2A1SLC2A3PIK3CASYK | |
| SCHEMBL27248739 | 0.78 | SLC2A1 (0.49) | DGAT1SLC2A1SLC2A3SYK | |
| SCHEMBL27248662 | 0.72 | SLC2A1 (0.52) | NPC1RAB9ADGAT1SLC2A1SLC2A3 | |
| SCHEMBL27249080 | 0.69 | SLC2A3 (0.67) | SLC2A1SLC2A3 | |
| SCHEMBL27249014 | 0.69 | SLC2A1 (0.51) | SLC2A1SLC2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | JAK1 3896/4885JAK3 3503/4885JAK2 1930/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | JAK1 3896/4885JAK3 3503/4885JAK2 1930/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | JAK1 3854/4885JAK3 2447/4885JAK2 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.